missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human Langerin Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (61%), Rat (61%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-82422 (PA5-82422. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Langerin (CD207) is a type II membrane-associated C-type lectin known to be expressed exclusively by Langerhans cells. Lamgerin recognizes mannose residues via its single carbohydrate recognition domain (CRD). Langerin is localized not only on the cell surface, but also intracellularly in close association with Birbeck granules. Transfection of Langerin cDNA into fibroblasts creates a compact network of membrane structures with typical features of Birbeck granules (BG). Langerin is thus a potent inducer of membrane superimposition and zippering leading to BG formation.
Specifications
Specifications
| Accession Number | Q9UJ71 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 50489 |
| Name | Human Langerin Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | CD 207 antigen; CD207; CD207 antigen; CD207 antigen, langerin; CD207 molecule; CD207 molecule, langerin; CLEC4K; C-type lectin domain family 4 member K; C-type lectin domain family 4, member K; Langerhans cell specific c-type lectin; langerin; RGD1565913 |
| Common Name | Langerin (CD207) |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction